INOVIQ Ltd products

INOVIQ has the exclusive worldwide license for SubB2M - an engineered protein that binds to a unique sugar molecule called Neu5Gc which is only present in human cancers. In initial clinical studies, SubB2M has detected cancers with 100% sensitivity and specificity for mid to late-stage cancers, and >95% specificity and 100% sensitivity for early-stage cancers. There is also evidence that Neu5Gc is present in a wide range of solid human tumors and can be detected in serum using SubB2M. SubB2M has the potential to detect cancer using liquid biopsies, immunoassays, circulating tumor cell assays and PET imaging.

INOVIQ’s NETs technology is a sample preparation platform with the potential to revolutionise the performance of liquid biopsy diagnostic assays. The market potential for liquid biopsy applications is estimated at billions of dollars annually.

INOVIQ has developed a proprietary immunocytochemistry (ICC) assay that detects hTERT, a component of telomerase, which is upregulated in most human epithelial cancers.

INOVIQ has three autoantibody tests in development for early detection of ovarian, breast and lung cancers. BARD1 autoantibody tests measure autoantibodies to variant BARD1 proteins in the blood and use a proprietary cancer-specific algorithm to combine these levels into a cancer score that identifies the presence or absence of a specific cancer. BARD1 autoantibodies reflect the body’s early immune response to tumour formation and are present in the early stages of cancer, enabling the BARD1 tests to detect cancer earlier across all cancer stages before symptoms appear.